Asthma Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Asthma Treatment Market
The asthma treatment market size was valued at USD 18.08 billion in 2019, and the market is now projected to grow USD 32.81 billion in 2032 exhibiting a CAGR of 4.6% during the forecast period of 2020-2032.
The appearance of COVID-19 posed some prospects in the asthma treatment market because any respiratory diseases became much more dangerous when this virus attacks the lungs. Symptomatic management of asthma and attempts to reduce progression of the illness to make a person less vulnerable to the severe course of COVID-19. Furthermore, the sales of inhalers and other asthma medication skyrocketed during the pandemic as people continued to cut their costs and made new worries about their health their top priority. The need for pulmonary care and regularly use of prescribed medications had to have driven the advancements and expanded marketing of asthma remedies.
The increase in the rate of chronic respiratory diseases especially asthma is helping to push the growth of the market for asthma treatments as asthma is the most prevalent chronic disease globally known. As observed previously, severe asthma still interferes with the Quality-of-life measure, and therefore the need for better drugs. Per the AAAAI survey done in 2016 an approximate of 8.3% of children in United States have asthma. There are also insights that the options of purchasing affordable and effective treatments will also remain crucial to the market’s development over the forecast period in addition.
One of the major trends in the asthma treatment market is the focus of leading pharma players on research and innovation to bring the best treatment line for asthma. Considering that asthma has a very broad patient pool globally including patient of all ages, many firms are developing drugs in clinical stages. For example, in September 2019, there was positive Phase III outcome of QVM149, an inhaled combination that controls asthmatic symptoms and lung function. Such clinical developments are anticipated to amplify the market more during the forecast period.
Comprehensive Analysis of Asthma Treatment Market
The asthma treatment market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly provides a thorough market breakdown near to the industry considering the leading supply and demand forces. These segmentations are methodically segregated by treatment analysis, by route of administration analysis and by distribution channel analysis. By treatment analysis include long-term control medications and quick-relief medications. By route of administration analysis include injectable, oral, and inhalation. By distribution channel analysis include hospital pharmacies, retail pharmacies & drug stores, and online pharmacies.
The North America region lead the asthma treatment market share by benefitting a market size of USD 9.40 billion in 2019 due to underdiagnosis of asthmatic patients.
The top players in the markets have a central responsibility in the healthcare industry to be sure of industrial prospectus development and to establish the market norms. These players include, AstraZeneca, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Mylan N.V., Boehringer Ingelheim International GmbH, Regeneron, Sanofi, Genentech, Inc. (F. Hoffmann-La Roche Ltd), Novartis AG, Sumitomo Dainippon Pharma Co., Ltd. these market players provide a level-playing competitive landscape.
In April 2020, Cipla Inc. announced the successful completion of a phase III clinical study for its generic asthma drug, fluticasone propionate and salmeterol inhalation powder, a generic equivalent of Advair Diskus 100/50 mcg.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD billion)
SegmentationBy Treatment
Long-Term Control Medications
Quick-Relief Medications
By Route of Administration
Injectable
Oral
Inhaled
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Online Pharmacies
By Geography
North America (U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia-Pacific)
Latin America (Brazil, Mexico, and the Rest of Latin America)
The Middle East & Africa (South Africa, GCC, and the Rest of the Middle East & Africa)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.